Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia'. Together they form a unique fingerprint.